Abstracts tagged "Lupus nephritis"

Abstract Number: 0842 • ACR Convergence 2025
Association of urinary biomarkers with histological features in diagnostic and per-protocol repeat kidney biopsies in lupus nephritis
Andrea Fava¹, CHEN-YU LEE¹, Carla Guthridge², Dionysis Nikolopoulos³, Julius Lindblom⁴, Farah Tamirou⁵, Michelle Petri⁶, Joel Guthridge², Frederic Houssiau⁷ and Ioannis Parodis⁸, ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Cliniques universitaires Saint-Luc, Brussels, Belgium, ⁶Johns Hopkins University School of Medicine, Timonium, MD, ⁷CUSL, BRUSSELS, Belgium, ⁸Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden
Background/Purpose: Persistent intrarenal inflammation despite immunosuppression drives kidney damage and functional decline in lupus nephritis (LN). Yet, current guidelines do not recommend repeat biopsy to…
Abstract Number: 0654 • ACR Convergence 2025
Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial
Ed Vital¹, Benni Vargas², Julie Rae², Tracey Wang³, Jason Hackney², Cary Looney⁴, William Pendergraft², Liz Lightstone⁵, Brad Rovin⁶, Richard Furie⁷ and Harini Raghu², ¹University of Leeds, Leeds, England, United Kingdom, ²Genentech, Inc., South San Francisco, CA, ³Hoffmann-La Roche Ltd, Missssauga, ON, Canada, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁵Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁶The Ohio State University, Columbus, OH, ⁷Division of Rheumatology, Northwell Health, Great Neck, NY
Background/Purpose: Lupus nephritis (LN) is characterized by kidney inflammation. B cells play a central role in LN pathogenesis and type I interferon (IFN-I) pathway activation…
Abstract Number: 1240 • ACR Convergence 2025
Serum Olink Proteomics Identifies Novel Mediators of Pain in Lupus Nephritis Patients Without Extrarenal Clinical Activity
Sarah Keegan¹, Philip Carlucci², Peter Izmirly³, Erin Carter⁴, Sanchit Sanyal⁵, Brooke Cohen⁶, Jasmine Shwetar⁷, Katie Preisinger⁸, Devyn Zaminski⁶, Kristina Deonaraine⁶, Mala Masson⁹, Andrea Fava¹⁰, Judith James¹¹, Rufei Lu¹¹, Wade DeJager¹², Chaim Putterman¹³, Michael Belmont¹⁴, Richard Furie¹⁵, Maria Dall'Era¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, Jennifer Anolik¹⁹, David Wofsy²⁰, Jennifer Barnas²¹, Nir Hacohen²², Robert Clancy²³, Joel Guthridge¹¹, Brad Rovin²⁴, Michelle Petri²⁵, Jill Buyon³ and Kelly Ruggles²⁶, ¹NYU Langone, New York, ²New York University School of Medicine, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶NYU Langone, NYC, ⁷New York University School of Medicine, Department of Medicine, New York, ⁸NYU Langone, NYU Langone, ⁹NYU Langone Medical Center- Division of Rheumatology, New York, NY, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Oklahoma Medical Research Foundation, Oklahoma City, ¹³Albert Einstein College of Medicine, Safed, Israel, ¹⁴NYU Langone Health, New York, NY, ¹⁵Division of Rheumatology, Northwell Health, Great Neck, NY, ¹⁶Division of Rheumatology, University of California, San Francisco, CA, ¹⁷Medical University of South Carolina, Johns Island, SC, ¹⁸UC San Diego, La Jolla, CA, ¹⁹University of Rochester Medical Center, Rochester, NY, ²⁰University of California San Francisco, SF, CA, ²¹University of Rochester, Rochester, NY, ²²Broad Institute of MIT Harvard, Cambridge, MA, ²³Columbia University, New York, NY, ²⁴The Ohio State University, Columbus, OH, ²⁵Johns Hopkins University School of Medicine, Timonium, MD, ²⁶NYU Grossman School of Medicine, Brooklyn, NY
Background/Purpose: For patients with lupus nephritis, active disease can be solely renal or include a range of extrarenal signs, such as arthritis or serositis, that…
Abstract Number: 1526 • ACR Convergence 2025
Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project
Ed Vital¹, George Bertsias², Andrea Doria³, Sindhu Johnson⁴, Sarah Mackie⁵, Sandra Navarra⁶, Bas Nijmeijer⁷, Ayobami Olojo⁷, Bernardo A. Pons-Estel⁸, Onno Teng⁹ and Jinoos Yazdany¹⁰, ¹University of Leeds, Leeds, England, United Kingdom, ²Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece, ³University of Padova, Padova, Italy, ⁴Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of Leeds, Leeds, United Kingdom, ⁶University of Santo Tomas, Manila, Philippines, ⁷AstraZeneca, Cambridge, United Kingdom, ⁸Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ⁹Leiden University Medical Center, Leiderdorp, Netherlands, ¹⁰UCSF, San Francisco, CA
Background/Purpose: Despite guidelines for SLE emphasizing the importance of tapering corticosteroids (CS), detailed recommendations on how to taper are limited. The purpose of this modified…
Abstract Number: 1846 • ACR Convergence 2025
Integrated spatial and single-cell profiling of treatment-naïve lupus nephritis biopsies
Roopa Madhu¹, Rachael Bogle², DANIEL STEIN³, JIngyi Cao⁴, Alex Tsoi², Caleb Marlin⁵, Thomas Eisenhaure⁶, Peter Izmirly⁷, Mala Masson⁸, Kevin Wei⁹, Victoria Werth¹⁰, Jennifer Barnas¹¹, Michael Brenner¹², Judith James⁵, Johann Gudjonsson¹³, Joel Guthridge⁵, Nir Hacohen¹⁴, Kelly Ruggles¹⁵, Soumya Raychaudhuri¹⁶, Jill Buyon¹⁷, Michelle Petri¹⁸, Brad Rovin¹⁹, Andrea Fava²⁰ and ilya Korsunsky¹⁶, ¹Brigham and Women's Hospital, Brookline, MA, ²University of Michigan, Holland, OH, ³Harvard University, Boston, ⁴BWH, Boston, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Broad Institute, Cambridge, MA, ⁷New York University Grossman School of Medicine, New York, NY, ⁸NYU Langone Health, New York, ⁹Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ¹⁰University of Pennsylvania, Wynnewood, PA, ¹¹University of Rochester, Rochester, NY, ¹²Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ¹³University of Michigan, Ann Arbor, MI, ¹⁴Broad Institute of MIT Harvard, Cambridge, MA, ¹⁵NYU Grossman School of Medicine, Brooklyn, NY, ¹⁶Brigham and Women's Hospital, Boston, MA, ¹⁷NYU Grossman School of Medicine, New York, NY, ¹⁸Johns Hopkins University School of Medicine, Timonium, MD, ¹⁹The Ohio State University, Columbus, OH, ²⁰Johns Hopkins University, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) is characterized by kidney inflammation and leads to loss of kidney function. Depending on race/ethnicity, up to 60% of Systemic Lupus…
Abstract Number: 2452 • ACR Convergence 2025
Preliminary Safety, Efficacy, and Cellular Kinetics of CTA311, a CD19 Targeted Universal CAR-T Therapy, for Active Autoimmune Diseases
Sanbin Wang¹, Heng Mei², Dongmei Zhou³, Wei Xie², Songlou Yin³, Chunmei Liu³, Hanwei Wang⁴, Huan Zhou⁵, Yue Xie⁶, Lu Han⁷, Jiangtao Ren⁸, Yali Zhou⁸, Wengang Ge⁷ and Jan Davidson-Moncada⁸, ¹⁹²⁰th Hospital of Joint Logistic Support Force, Kunming, China (People's Republic), ²Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic), ³The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China (People's Republic), ⁴The Third People’s Hospital of Bengbu, Beng bu, China (People's Republic), ⁵Clinical Research Hospital of the First Affiliated Hospital of Anhui Medical University, Hefei, China (People's Republic), ⁶Bioheng Therapeutics Limited, Nan Jing Shi, China (People's Republic), ⁷Bioheng Therapeutics Co., Limited, Nanjing, China (People's Republic), ⁸Bioheng Therapeutics Co., Limited, Nan Jing, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) and anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) are autoimmune conditions characterized by B cell activation, autoreactivity, and autoantibody production. CAR-T therapy…
Abstract Number: 0851 • ACR Convergence 2025
Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis
CHEN-YU LEE¹, Sepehr Taghavi², Shangzhu Zhang³, Roopa Madhu⁴, Jasmine Shwetar⁵, Tyler O'Malley⁶, Daniel Goldman⁷, Peter Izmirly⁸, H Michael Belmont⁹, Richard Furie¹⁰, Noa Schwartz¹¹, Chaim Putterman¹², Jennifer Barnas¹³, Jennifer Anolik¹⁴, Sarah French¹⁵, Maria Dall'Era¹⁶, Judith James¹⁷, Joel Guthridge¹⁷, Jacob Vasquez¹⁸, Mike Nerenberg¹⁹, Andrew Concoff²⁰, Christine Schleif²¹, Kevin Wei²², Thomas Eisenhaure²³, Nir Hacohen²³, Rachael Bogle²⁴, Johann Gudjonsson²⁵, Lam Tsoi²⁵, Brad Rovin²⁶, Jill Buyon²⁷, Michelle Petri⁷ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²Exagen Inc, Escondido, CA, ³Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China (People's Republic), ⁴Brigham and Women's Hospital, Brookline, MA, ⁵New York School of Medicine, Ann Arbor, MI, ⁶Exagen, Vista, CA, ⁷Johns Hopkins University School of Medicine, Timonium, MD, ⁸New York University Grossman School of Medicine, New York, NY, ⁹NYU School of Medicine, New York, NY, ¹⁰Division of Rheumatology, Northwell Health, Great Neck, NY, ¹¹Division of Rheumatology, Department of Medicine, Montefiore Medical Center, New York, NY, ¹²Albert Einstein College of Medicine, Safed, Israel, ¹³University of Rochester, Rochester, NY, ¹⁴University of Rochester Medical Center, Rochester, NY, ¹⁵UCSF, Mill Valley, CA, ¹⁶Division of Rheumatology, University of California, San Francisco, CA, ¹⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Exagen, Inc., Vista, CA, ¹⁹Exagen, DEL MAR, CA, ²⁰Specialty Networks/United Rheumatology, a Cardinal Health Company, N/A, ²¹Exagen, Carlsbad, CA, ²²Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ²³Broad Institute, Cambridge, MA, ²⁴University of Michigan, Holland, OH, ²⁵University of Michigan, Ann Arbor, MI, ²⁶The Ohio State University, Columbus, OH, ²⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: Kidney survival is the ultimate treatment goal in lupus nephritis (LN), but long-term predictors remain understudied due to the need for extensive follow up.…
Abstract Number: 0655 • ACR Convergence 2025
Blood pressure remains elevated in patients initiating voclosporin with low baseline blood pressure: evidence from patients in routine clinical care
Eric Roberts¹, gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, SF, CA, ²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: Hypertension was a common adverse event in RCTs testing voclosporin, an oral calcineurin inhibitor approved in 2021 to treat lupus nephritis (LN). In these…
Abstract Number: 1258 • ACR Convergence 2025
Upadacitinib in the treatment of Rheumatoid Arthritis – Interstitial Lung Disease. National multicenter study of 25 patients in clinical practice.
Ana Serrano-Combarro¹, Belén Atienza-mateo², Leticia del Olmo Perez³, Sara García-Perez⁴, Guillermo Gonzalez Mozo de Rosales⁵, Jose Rosas Gómez de Salazar⁶, ana Urruticoechea-Arana⁷, Andrea García-Valle⁸, Jesús Loarce⁹, Paula García-Escudero¹⁰, Bryan Josué Flores Robles¹¹, Rafael B. Melero-González¹², Alicia Garcia¹³, Maria Martín López¹⁴, Patricia López Viejo¹⁵, Maria Jose Perez Gaan¹⁶, Nuria Vegas Revenga¹⁷, Angel Garcia-Aparicio¹⁸, M.Pilar Bernabeu Gonzalvez¹⁹, Juan Moreno Morales²⁰ and Ricardo Blanco²¹, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, ³HGU Nuestra Señora del Prado, Talavera de la Reina, Talavera de la Reina, Spain, ⁴Complejo Hospitalario de Vigo, Vigo, Spain, ⁵Basurto University Hospital, Bilbao, Spain, ⁶Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ⁷Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, ⁸Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, ⁹Ramón y Cajal University Hospital, Madrid, Spain, ¹⁰Hospital Universitario Álava, Bilbao, Spain, ¹¹Hospital San Pedro, Logroño, Spain, ¹²COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ¹³Rheumatologist, La Laguna, Spain, ¹⁴Hospital ¹² de Octubre, Madrid, Spain, ¹⁵Hospital Severo Ochoa (Leganés), Leganes, Spain, ¹⁶Hospital Universitario Virgen de las Nieves, Granada, Spain, ¹⁷Galdakao- Usansolo University Hospital, Galdakao, Spain, ¹⁸Hospital Universitario de Toledo, Toledo, Spain, ¹⁹Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ²⁰Hospital Universitario Santa Lucia Cartagena, Cartagena, Spain, ²¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and rituximab are usually the recommended drugs. JAK inhibitors (JAKi)…
Abstract Number: 1527 • ACR Convergence 2025
Lupus Nephritis Clinical Practice Guidelines: Critical Appraisal and Quality Comparison Using the AGREE II Tool
Egla Samantha Sanchez-Peralta¹, Hector Alejandro Martinez-Espinosa¹, Karla Paola Moncada-Flores², Margarita Isabel Alarcon-Jarquin³, Dionicio A. Galarza-Delgado⁴, Diana E. Flores-Alvarado¹ and Gabriel Figueroa-Parra⁵, ¹Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, ²Internal Medicine, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
Background/Purpose: About a half of the patients with systemic lupus erythematosus (SLE) can present lupus nephritis (LN) throughout the course of their disease, representing one…
Abstract Number: 1847 • ACR Convergence 2025
Spatial transcriptomics reveals a complex microanatomic patterning of complement mediated inflammation and fibrosis in Class III pediatric lupus nephritis associated with local histologic injury
Sarah McCuaig¹, Julia Rood¹, Em Elliott¹, Portia Kreiger¹ and Edward Behrens², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²CHOP, West Chester, PA
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of patients with pediatric systemic lupus erythematosus (pSLE) and results in significant morbidity due to suboptimal kidney…
Abstract Number: 2453 • ACR Convergence 2025
Belimumab Is Associated with Lower Risk of Progression to LN Compared with Standard of Care in Patients with SLE
Maral DerSarkissian¹, Yan Chen¹, Ariel Chao¹, Shumin Rui¹, Bronwyn Moore², Karen Worley³, Daniel Moldaver⁴, Jeffrey J. Ellis³ and Aarat M Patel⁵, ¹Analysis Group, Los Angeles, CA, ²Analysis Group, Montreal, QC, Canada, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, ⁴GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ⁵GSK, US Medical Affairs, Durham, NC
Background/Purpose: LN develops in ~40% of patients with SLE and is associated with increased risk of morbidity, including end-stage kidney disease, and mortality. Belimumab, a…
Abstract Number: 0601 • ACR Convergence 2025
Precipitants and Long-Term Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort Study and Systematic Review
Ali Ardekani¹, Alain Sanchez-Rodriguez², Mariana González-Treviño³, Jose Meade-Aguilar⁴, Maria O. Valenzuela-Almada⁵, Hannah Langenfeld¹, Larry J. Prokop⁴, Isabel Valenzuela Almada⁶, Gabriel Figueroa-Parra⁷, Nicolás Sánchez Domínguez⁸, Alejandro A. Rabinstein⁴, M. Hassan Murad⁴, Cynthia Crowson⁹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²ABC Medical Center, Ciudad de México, Federal District, Mexico, ³Vanderbilt University Medical Center, Nashville, ⁴Mayo Clinic, Rochester, ⁵Children’s National Medical Center, Washington D.C, ⁶Universidad Panamericana, Ciudad de México, Federal District, Mexico, ⁷Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁸Clínica Alemana de Santiago, Santiago, Chile, ⁹Mayo Clinic, Stewartvillle, MN
Background/Purpose: Posterior reversible encephalopathy syndrome (PRES) is an underrecognized neuroradiologic complication of SLE, characterized by acute neurological symptoms and vasogenic edema on neuroimaging. Its precipitating…
Abstract Number: 0661 • ACR Convergence 2025
Real-world Effectiveness and Usage of Voclosporin: Data from the Enlight-LN Registry
Leanna Wise¹, Laura Geraldino-Pardilla², Niloofar Nobakht³, Mohammad Kamgar³, Amber Rosales⁴, Barbara McIntosh⁴ and Ron Flauto⁴, ¹LAGMC/Keck Medicine of USC, Los Angeles, ²Columbia University, New York, NY, ³University of California Los Angeles, Los Angeles, CA, ⁴Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada
Background/Purpose: The 2024 American College of Rheumatology Lupus Nephritis (LN) Guideline recommends triple immunosuppressive therapy, including the option of a calcineurin inhibitor (CNI)-based regimen, for…
Abstract Number: 1273 • ACR Convergence 2025
Effectiveness of IV Cyclophosphamide and Mycophenolate Mofetil in the Treatment of Pediatric Systemic Lupus Erythematosus with Lupus Nephritis
adrienne katrin guiang-valerio, University of Santo Tomas Hospital, Mandaluyong, National Capital Region, Philippines
Background/Purpose: Lupus nephritis (LN) is more common in children (occurs in 50-82%) compared to adults. Cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are both treatment options…

« Previous Page
1
…
4
5
6
7
8
…
44
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].